CLINICAL TRIAL
What is the MyopiaX® clinical trial about?
The purpose of this trial is to investigate the efficacy of MyopiaX®
MyopiaX® is a smartphone application that provides a treatment to slow the progression of myopia in children and adolescents. We are conducting a clinical trial (NCT04967287) to investigate the safety andefficacy of MyopiaX® to control the progression of myopia. Used in combination with a virtual reality headset and wireless controller, the MyopiaX® app is designed to provide and achieve a medical treatment. Intended to be used twice a day, each session with MyopiaX® is several minutes long and delivers our patented, light-based technology treatment with a child-friendly virtual reality game.
The MyopiaX® clinical trial is including…
- Children between the ages of 6 and 14 years with progressive myopia starting at -0.75 Diopters
- Six visits to the clinic over a 24-month period
- At-home treatment two times every day
- Five scheduled phone call evaluations between the visits, from the research specialist at the clinic
- A 12-month follow-up period after the end of the 24 months treatment, with two additional visits to the clinic
- Six research clinics located in Ireland, Germany, Portugal, Spain, and the Netherlands.
The study has been reviewed and approved to be conducted by the regulatory authorities and ethics committees of the respective clinical institutions in each country to ensure participants‘ safety and well-being throughout the trial.
Why should children with myopia participate?
- Participants will have access to regular eye examinations and ophthalmological check-up assessments by international researchers with expertise in myopia and children’s eye care at recognized research and clinical centres
- Participants will contribute valuable information to the scientific understanding of myopia and the development of treatments for myopia progression
- Participants will be part of a group of peers from across Europe who are participating in the same study.
Interested in learning more?
For more information, contact us at clinicaltrials@dopavision.com or get in touch with a research specialist from one of the clinics below. Researchers and clinicians are also welcome to use this e-mail address to reach out to us with questions or for more information.
Find a trial site
Germany
Düsseldorf
MVZ Makula-Netzhaut-Zentrum Breyer Kaymak Klabe
Dr. Hakan Kaymak
netzhaut@augenchirurgie.clinic
+49 211 2730410
Tübingen
University Eye Hospital Tübingen
Ireland
Netherlands
Rotterdam
Erasmus University Medical Center
Trialbureau Oogheelkunde Erasmus MC
onderzoek.oogheelkunde@erasmusmc.nl
+31 10 7039740
Spain
Madrid
University Complutense of Madrid
Ocupharm Research Group
investigacionesocupharm@gmail.com
+34 611 63 84 34
Our Partners
Dopavision is funded as part of the BMBF’s Industry-in-Clinic Platform Program (FKZ: 13GW0256)